These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36455593)

  • 1. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities.
    Morin S; Segafredo G; Piccolis M; Das A; Das M; Loffredi N; Larbi A; Mwamelo K; Villanueva E; Nobre S; Burrone E
    Lancet Glob Health; 2023 Jan; 11(1):e145-e154. PubMed ID: 36455593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study.
    Morin S; Moak HB; Bubb-Humfryes O; von Drehle C; Lazarus JV; Burrone E
    Lancet Public Health; 2022 Feb; 7(2):e169-e176. PubMed ID: 34710359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries.
    Calamia M; Abraham I
    Expert Opin Biol Ther; 2023; 23(8):653-657. PubMed ID: 37578070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to Vaccines and Medicines in Low- and Middle-Income Countries.
    Fox A
    J Health Polit Policy Law; 2024 Feb; 49(1):43-72. PubMed ID: 37522368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
    Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
    J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
    Ewen M; Zweekhorst M; Regeer B; Laing R
    PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story.
    Gore C; Morin S; Røttingen JA; Kieny MP
    BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37669799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level.
    Todesco B; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2022 Apr; 31():e22. PubMed ID: 35438063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis.
    Son KB
    Global Health; 2019 Jun; 15(1):42. PubMed ID: 31248441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.
    Muhsen IN; Hashmi SK; Niederwieser D; Kroeger N; Agrawal S; Pasquini MC; Atsuta Y; Ballen KK; Seber A; Saber W; Kharfan-Dabaja MA; Rasheed W; Okamoto S; Khera N; Wood WA; Koh MBC; Greinix H; Kodera Y; Szer J; Horowitz MM; Weisdorf D; Aljurf M
    Bone Marrow Transplant; 2020 Apr; 55(4):698-707. PubMed ID: 31484992
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.